Abstract:Abstract Background LKB1 is a protein kinase that is mutated and down-regulated in 20-30% of NSCLC. LKB1 mutations co-occur with KRAS alterations in 7%-10% of NSCLC, resulting in an aggressive phenotype with short survival, and frequent metastases. Because LKB1 activates AMPK, many of the best known functions of LKB1 are attributed to its ability to control metabolic alterations in the cells. However LKB1 also plays an important role in regulating tumor progression, metastasis and angiogenesis, likely as a compensatory strategy to overcome energetic depletion of tumor microenvironment. Bevacizumab, the anti-VEGF antibody improves PFS in NSCLC patients combined with chemotherapy but the benefit is modest and transient and often patients develop resistance. Our laboratory has identified alterations in cell metabolism and in vasculature of LKB1 deficient tumors when compared to LKB1 wild type. These findings may indicate that loss of LKB1 could alter the tumor vasculature in NSCLC. Methods mRNA expression of angiogenesis related genes were analyzed in wild type and LKB1 deficient NSCLC tumors (TCGA). In vitro validation was performed by qPCR and western blot. CD31 IHC was performed to analyze microvasculature density (MVD) in Krasmut and Krasmut LKB1f/f mice tumors. HUVEC tube formation and migration assays were performed with conditioned medium of LKB1 expressing and deficient NSCLC isogeneic cell lines. Xenograft NSCLC models were established via s.c. injection of H460 (LKB1 deficient) and H460 LKB1 (LKB1 expressing) cells in nude mice. Treatment consisting of human and/or mouse bevacizumab and nintedanib were administrated. Tumor volumes were measured and vasculature analysis was performed. Results In vitro HUVEC cells exhibited an increase migration and differences in endothelial network formation when incubated with conditioned medium from LKB1 deficient cells compared to LKB1 expressing cells medium (p<0.05). LKB1 deficient cells upregulated hypoxia and energetic stress related genes (HIF1AN, EGLN1, HIF3A, EPAS1 and CA12) and increased the secretion of angiogenesis related factors (VEGF, IL8, endoglin). IHC analysis of baseline CD31 expression of tumors from Krasmut and Krasmut LKB1f/f mutant mice showed no significant differences in MVD. However, anti-angiogenic therapy significantly inhibited tumor progression in LKB1 expressing xenografts but did not show any therapeutic effect in LKB1 deficient tumors. LKB1 expressing xenografts treated with human or mouse bevacizumab, or the combination of both and nintedanib, resulted in a significant decrease in tumor volume (p<0.05). The blockade of human and mouse VEGF showed an optimal therapeutic effect with approximately 70% reduction of tumor volume (p<0.001). Conclusions LKB1 deficiency may promote resistance to anti-angiogenic therapy by regulating compensatory angiogenic pathways along metabolic adaptations to energetic stress in NSCLC. Citation Format: Irene Guijarro, Alissa Poteete, Chao Yang, Emily Roarty, Monique Nilsson, Huiying Sun, Pan Tong, Edward Chang, Jaime Rodriguez-Canales, Barbara Mino, Edwin Parra, Ignacio Wistuba, Jing Wang, Timothy Heffernan, John V. Heymach. LKB1 loss is associated with resistance to VEGF inhibitors in non-small cell lung cancer (NSCLC). [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3272.

Abstract 4173: IKBKE/IKKα is a prognostic marker and is required for KRAS-driven tumorigenecity in non-small cell lung cancer

Abstract 4991: Upregulation and the role of IKBKE in non-small cell lung cancer

Abstract 4416: IKBKE is a key mediator of Ras activation of NF-κB and Ras oncogenic function

Abstract 1890: IKBKE is a Substrate of EGFR and a Therapeutic Target in NSCLCs with Activating Mutations of EGFR

Abstract LB-144: I-kappa-B kinase (IKK)ε expression in pancreatic ductal adenocarcinoma

Kinome Expression Profiling Identifies IKBKE As a Predictor of Overall Survival in Clear Cell Renal Cell Carcinoma Patients.

Supplemental Figure 4 from IKBKE is a Substrate of EGFR and a Therapeutic Target in Non–Small Cell Lung Cancer with Activating Mutations of EGFR

Abstract LB-310: Small molecule inhibitors of IKBKE with antitumor activity in cancer cells overexpressing IKBKE .

Abstract A110: Kinase Gene Expression Profiles Are Associated with Clinical Outcomes in Clear Cell Renal Cell Carcinoma Patients

Abstract 4634: Inhibitory-κB kinase alpha as a biomarker and therapeutic target in colorectal cancer

Abstract 1428: Upregulation of IKBKE promotes glioma cell migration and invasion by phosphorylation of Snail

Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer.

Abstract 2150: LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant non-small cell lung cancers to combined KRAS G12C + MCL-1 blockade

Abstract 3255: IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer

IKBKE is over-expressed in glioma and contributes to resistance of glioma cells to apoptosis via activating NF-κB.

IKKα Inactivation Promotes Kras-initiated Lung Adenocarcinoma Development Through Disrupting Major Redox Regulatory Pathways.

Abstract 4372: Evaluating TBK1 as a cancer therapeutic target in cancer cell lines with activated IRF3.

Abstract 3272: LKB1 Loss is Associated with Resistance to VEGF Inhibitors in Non-Small Cell Lung Cancer (NSCLC)

Abstract 773: Restoration of LKB1 Defect in EKVX Cells Leads to Resistance to Microtubule Targeting Agents

Abstract 652: Tumor cell-specific IL-1/IL-1R signaling promotes KRAS mutant lung tumorigenesis

Advances in IKBKE as a potential target for cancer therapy